India boasts numerous top-tier, high-quality companies and presents a wide array of opportunities for long-term investors, highlighting the untapped potential.
Exploring the growth potential of the Indian pharmaceutical sector requires careful consideration of risks and uncertainties, demanding thorough research before investing in a pharma fund.
The Indian pharmaceutical sector holds significant growth potential, yet it is crucial to acknowledge the accompanying risks and uncertainties. Before making any commitments to invest in a pharma fund, thorough research is imperative.
Samir Arora of Helios Capital discusses valuation, investment strategies, and risk management in the Indian market. He emphasizes the missed opportunity in the pharma sector and the underperformance of the consumer sector. He said willing to buy consumer stocks at 40-50 PE if the companies are growing 25-30% per annum for the next few years at least. That is the only thing we will buy in consumer even if the valuations are high. That is why we have Zomato and Varun Beverages .
Andrew Holland, CEO of Avendus Capital Alternate Strategies, believes that PSU banks are performing well while private banks face challenges. He also comments on the rotational market, pharma and IT sectors, OMCs, metal stocks, and the global market dynamics. He also says, he likes metal stocks a lot, That is an area which will see continued rise over the course of the next month.